Researchers have uncovered a promising mechanism for combating intervertebral disc degeneration (IDD) by leveraging the growth factor FGF21 to upregulate the sirtuin SIRT1, enhancing mitophagy in spinal disc cells. Published in Aging Cell, the study demonstrated that FGF21 administration delayed IDD in a rat model, suggesting a novel therapeutic avenue for addressing a common cause of lower back pain in aging populations.

The significance of this finding lies in its dual focus on cellular senescence and mitochondrial health. As FGF21 levels decline with age, its potential to improve mitophagy—the process of removing damaged mitochondria—becomes critical. The research revealed that FGF21 not only reduced key senescence markers but also restored antioxidant production and ATP synthesis in stressed disc cells. This indicates that targeting mitochondrial health through FGF21 could mitigate the cellular aging processes associated with IDD, a condition that has been a persistent challenge in anti-aging research.

A key takeaway from this study is the established causal pathway: FGF21 upregulates SIRT1, which activates the PINK1-Parkin pathway to promote mitophagy and reduce cellular senescence. While the results are promising, further investigation is needed to determine the applicability of these findings to naturally aged organisms and humans. This research highlights the potential of growth factors like FGF21 in developing therapeutic strategies aimed at enhancing healthspan and mitigating age-related degenerative conditions.

Source: lifespan.io